IP Library Granted Patent US 8,618,267
Granted Patent B2
US 8,618,267 · App. 13/083,152 · Granted Dec 31, 2013

PEG-urate oxidase conjugates and use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,618,267
App. No.
13/083,152
Granted
Dec 31, 2013
Kind
B2
Abstract

A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme.

Claims (10)

1. A method for isolating a tetrameric form of urate oxidase (uricase) from a solution of purified uricase comprising tetrameric uricase and uricase aggregates, said method comprising:

(a) separating the solution into fractions on at least one separation column at a pH between about 9 and about 10.5, wherein said column is selected from the group consisting of an ion-exchange column and a size-exclusion column; and

(b) recovering from said column one or more fractions that contain isolated tetrameric uricase, wherein greater than 90% of said isolated uricase in said one or more fractions is in a tetrameric form.

2. The method of claim 1 , wherein said separating is performed at a pH of 10.2.

3. The method of claim 1 , wherein said separating is performed at a pH of 10 to 10.5.

4. The method of claim 1 , further comprising analyzing said one or more fractions to determine at least one property thereof selected from the group consisting of the presence of said tetrameric unease and the absence of said unease aggregates.

5. The method of claim 4 , wherein said analyzing comprises at least one analytical method selected from the group consisting of chromatography, centrifugation, light scattering and electrophoresis.

6. The method of claim 5 , wherein said analytical method is high performance liquid chromatography.

7. The method of claim 1 , wherein the uricase in said solution is selected from the group consisting of recombinant mammalian uricase, uricase from Candida utilis , recombinant soybean uricase, uricase from Arthrobacter globiformis , porcine uricase, and baboon uricase.

8. The method of claim 7 , wherein said uricase is one or more of chimeric, amino-terminally truncated, carboxyl-terminally truncated, amino-terminally and carboxyl-terminally truncated, and mutated.

Assignments (12)
RELEASE OF SECURITY INTEREST Recorded Oct 6, 2023
From: CITIBANK, N.A.
To: HORIZON THERAPEUTICS USA, INC.
Reel/Frame 065178/0965 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2023
From: HORIZON PHARMA RHEUMATOLOGY LLC
To: HORIZON THERAPEUTICS USA, INC.
Reel/Frame 062294/0205 →
CHANGE OF NAME Recorded Nov 18, 2016
From: CREALTA PHARMACEUTICALS LLC
To: HORIZON PHARMA USA RHEUMATOLOGY LLC
Reel/Frame 040648/0361 →
CHANGE OF NAME Recorded Nov 18, 2016
From: HORIZON PHARMA USA RHEUMATOLOGY LLC
To: HORIZON PHARMA RHEUMATOLOGY LLC
Reel/Frame 040648/0367 →
PATENT SECURITY AGREEMENT Recorded Sep 16, 2016
From: HORIZON PHARMA RHEUMATOLOGY LLC (FORMERLY KNOWN AS CREALTA PHARMACEUTICALS LLC)
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 040059/0007 →
RELEASE OF SECURITY INTEREST Recorded Jan 13, 2016
From: JEFFERIES FINANCE LLC, AS COLLATERAL AGENT
To: CREALTA PHARMACEUTICALS LLC
Reel/Frame 037483/0163 →
RELEASE OF SECURITY INTEREST Recorded Jan 13, 2016
From: FIFTH STREET FINANCE CORP., AS COLLATERAL AGENT
To: CREALTA PHARMACEUTICALS LLC
Reel/Frame 037483/0073 →
SECURITY INTEREST Recorded Aug 11, 2015
From: CREALTA PHARMACEUTICALS LLC
To: FIFTH STREET FINANCE CORP., AS COLLATERAL AGENT
Reel/Frame 036300/0073 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2015
From: MOUNTAIN VIEW PHARMACEUTICALS, INC.
To: CREALTA PHARMACEUTICALS LLC
Reel/Frame 036240/0827 →
SECURITY INTEREST Recorded Jul 21, 2015
From: CREALTA PHARMACEUTICALS LLC
To: JEFFERIES FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 036142/0931 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2011
From: HERSHFIELD, MICHAEL S.; KELLY, SUSAN J.
To: DUKE UNIVERSITY
Reel/Frame 027020/0822 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2011
From: WILLIAMS, L. DAVID; SAIFER, MARK G.P.; SHERMAN, MERRY R.
To: MOUNTAIN VIEW PHARMACEUTICALS, INC.
Reel/Frame 027020/0843 →